Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 211 of the 212 references it cites were found in a registry or an index; 81 of the 214 sources its claims cite were checked for support.

Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society

Open access

Abstract

Recent advances in human genetics, together with a large body of epidemiologic, preclinical, and clinical trial results, provide strong support for a causal association between triglycerides (TG), TG-rich lipoproteins (TRL), and TRL remnants, and increased risk of myocardial infarction, ischaemic stroke, and aortic valve stenosis. These data also indicate that TRL and their remnants may contribute significantly to residual cardiovascular risk in patients on optimized low-density lipoprotein (LDL)-lowering therapy. This statement critically appraises current understanding of the structure, function, and metabolism of TRL, and their pathophysiological role in atherosclerotic cardiovascular disease (ASCVD). Key points are (i) a working definition of normo- and hypertriglyceridaemic states and their relation to risk of ASCVD, (ii) a conceptual framework for the generation of remnants due to dysregulation of TRL production, lipolysis, and remodelling, as well as clearance of remnant lipoproteins from the circulation, (iii) the pleiotropic proatherogenic actions of TRL and remnants at the arterial wall, (iv) challenges in defining, quantitating, and assessing the atherogenic properties of remnant particles, and (v) exploration of the relative atherogenicity of TRL and remnants compared to LDL. Assessment of these issues provides a foundation for evaluating approaches to effectively reduce levels of TRL and remnants by targeting either production, lipolysis, or hepatic clearance, or a combination of these mechanisms. This consensus statement updates current understanding in an integrated manner, thereby providing a platform for new therapeutic paradigms targeting TRL and their remnants, with the aim of reducing the risk of ASCVD.

Overview

CoChat Summary

TL;DR

This European Atherosclerosis Society consensus statement appraises evidence that triglyceride-rich lipoproteins (TRL) and their remnants are causally related to atherosclerotic cardiovascular disease (ASCVD), including myocardial infarction, ischaemic stroke, and aortic valve stenosis, and contribute to residual risk on optimized LDL-lowering therapy. It reviews TRL metabolism, remnant atherogenicity, measurement challenges, and emerging therapeutic strategies targeting production, lipolysis, or hepatic clearance.

Key findings

  • Epidemiologic and genetic evidence supports a causal relationship between elevated plasma TG, TRL, and TRL remnants and ASCVD risk; the absolute risk increase is greatest for myocardial infarction (approximately four-fold at TG >5 mmol/L or >440 mg/dL vs. <1 mmol/L or <88 mg/dL), and less for ischaemic stroke and aortic stenosis.
  • TRL and remnants accumulate at fasting TG levels >1.2 mmol/L (>100 mg/dL); ASCVD risk is considered clinically relevant at fasting TG >1.7 mmol/L (>150 mg/dL), while TG >10 mmol/L (>880 mg/dL) confers high pancreatitis risk.
  • Cholesterol-rich remnant particles can contain up to four-fold more cholesterol molecules than LDL (up to 10,000 vs. 2,000–2,700 cholesterol molecules per particle), are enriched in apoE and apoCIII, and are more potent inducers of macrophage foam cells than LDL on a per-particle basis.
  • Therapeutic approaches include inhibiting lipoprotein production, reducing cholesteryl ester enrichment of remnants, stimulating lipolysis, and enhancing remnant clearance; however, no definitive measure captures the independent atherogenic potential of TRL and remnants, and randomized controlled trial evidence that lowering TG/TRL reduces ASCVD risk is limited.

Methods

  • Consensus statement from a European Atherosclerosis Society Consensus Panel that met in London in January 2020 to critically appraise evidence on TRL and remnant definition, aetiology, metabolism, role in ASCVD, and clinical management.
  • References (English language only) were identified through PubMed searches for articles published from 2000 using terms including “triglycerides,” “lipoprotein remnants,” “triglyceride-rich lipoproteins,” “cardiovascular disease,” “atherosclerosis,” “residual risk,” and “therapeutics,” plus reference-list searches.
  • The paper is a narrative expert synthesis of epidemiologic, genetic, preclinical, and clinical trial evidence, not a systematic review or meta-analysis.

Limitations

  • The paper states that there is no definitive measure capturing the independent atherogenic potential, structural and metabolic variability, or postprandial changes of TRL and remnants; defining remnants is difficult, and proposed TG cut-points are arbitrary though considered clinically useful.
  • The paper states that there are no treatment goals for plasma TG or remnant abundance given limited randomized controlled trial evidence that lowering TG or TRL reduces ASCVD risk, and that determining the relative atherogenicity of TRL/remnants vs. LDL will require specific assays.
  • Evident from the text: the search strategy was limited to English-language PubMed articles from 2000 onward plus reference lists, and the conclusions are consensus-based expert opinion rather than systematic quantitative synthesis.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehab551

Cites

211 of 211 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Graphical abstract Formation of triglyceride-rich lipoprotein remnants and their role in atherogenesis. Metabolic scheme for the generation and clearance of triglyceride-rich lipoprotein remnant particles (A). In hypertriglyceridaemia, overproduction and inefficient lipolysis of both very low-density lipoprotein and chylomicrons lead to increased remnant formation. Triglyceride-rich lipoprotein remnants contribute to the initiation and progression of atherosclerotic lesions (B). Particle retention in the subendothelial space is followed by inflammation, cholesterol deposition, and macrophage foam cell formation.
Graphical abstract Formation of triglyceride-rich lipoprotein remnants and their role in atherogenesis. Metabolic scheme for the generation and clearance of triglyceride-rich lipoprotein remnant particles (A). In hypertriglyceridaemia, overproduction and inefficient lipolysis of both very low-density lipoprotein and chylomicrons lead to increased remnant formation. Triglyceride-rich lipoprotein remnants contribute to the initiation and progression of atherosclerotic lesions (B). Particle retention in the subendothelial space is followed by inflammation, cholesterol deposition, and macrophage foam cell formation.CC BY-NC · PubMed Central
Figure 3 Absolute risk of cardiovascular morbidity as a function of increasing non-fasting plasma triglycerides in the general population. Based on data from more than 100 000 individuals in the Copenhagen General Population Study, as derived from refs.11,17,27,28 ASCVD, atherosclerotic cardiovascular disease.
Figure 3 Absolute risk of cardiovascular morbidity as a function of increasing non-fasting plasma triglycerides in the general population. Based on data from more than 100 000 individuals in the Copenhagen General Population Study, as derived from refs.11,17,27,28 ASCVD, atherosclerotic cardiovascular disease.CC BY-NC · PubMed Central
Figure 1 Size and density profile of major apolipoprotein B-containing lipoprotein classes. This schematic depicts the spectrum of apolipoprotein (apo) B-containing lipoproteins (VLDL, IDL, LDL—very low-, intermediate-, and low-density lipoproteins, respectively), their density and size (diameter in nm), distribution, and their content of triglyceride and cholesteryl ester (as percent of mass). The stylized distribution of the relative amount of remnant particles in subjects with optimal triglyceride (<1.2 mmol/L) and elevated triglyceride (3.0 mmol/L) is shown for apoB100 (orange) and apoB48 (blue) containing lipoproteins. The profile of ‘apoB48 remnants’ is based on the apoB48 concentrations in VLDL1, VLDL2, and IDL in the late (post-peak) phase of lipid absorption and after an overnight fast, whereas that of ‘apoB100 remnants’ is based on the concentration of apoB100 in VLDL2 and IDL. Based on data from Björnson et al.3 CE, cholesteryl ester; IDL, intermediate-density lipoprotein; LDL, low-density lipoprotein; TG, triglyceride; VLDL, very low-density lipoprotein.
Figure 1 Size and density profile of major apolipoprotein B-containing lipoprotein classes. This schematic depicts the spectrum of apolipoprotein (apo) B-containing lipoproteins (VLDL, IDL, LDL—very low-, intermediate-, and low-density lipoproteins, respectively), their density and size (diameter in nm), distribution, and their content of triglyceride and cholesteryl ester (as percent of mass). The stylized distribution of the relative amount of remnant particles in subjects with optimal triglyceride (<1.2 mmol/L) and elevated triglyceride (3.0 mmol/L) is shown for apoB100 (orange) and apoB48 (blue) containing lipoproteins. The profile of ‘apoB48 remnants’ is based on the apoB48 concentrations in VLDL1, VLDL2, and IDL in the late (post-peak) phase of lipid absorption and after an overnight fast, whereas that of ‘apoB100 remnants’ is based on the concentration of apoB100 in VLDL2 and IDL. Based on data from Björnson et al.3 CE, cholesteryl ester; IDL, intermediate-density lipoprotein; LDL, low-density lipoprotein; TG, triglyceride; VLDL, very low-density lipoprotein.CC BY-NC · PubMed Central
Figure 2 Physicochemical characteristics of remnant lipoproteins. (A) Remnant lipoproteins are partially lipolysed products of lipoprotein lipase action. They have a triglyceride-depleted core and are enriched in cholesteryl esters. The main structural protein is apolipoprotein (apo)B48 in chylomicron remnants and apoB100 in very low-density lipoprotein remnants. A typical normal-sized low-density lipoprotein particle is shown for comparison. (B) Comparison of the cholesterol/apoB molar ratios in remnant-like particles isolated by immunoaffinity gel from the plasma of fasting subjects with Type III dyslipoproteinaemia, in which remnant particles accumulate, or borderline or moderately elevated triglyceride levels (data extracted from ref5). Only traces of remnant particles were detected in subjects with borderline elevated triglyceride levels. apo, apolipoprotein; CETP, cholesteryl ester transfer protein; HDL, high-density lipoprotein; HSPG, heparan sulphate proteoglycans; LDLr, low-density lipoprotein receptor; LRP1, low-density lipoprotein receptor-related protein 1; mol, molecules; RLP, remnant-like particle; RLP-C, remnant-like particle cholesterol; TG triglyceride; TRL, triglyceride-rich lipoproteins.
Figure 2 Physicochemical characteristics of remnant lipoproteins. (A) Remnant lipoproteins are partially lipolysed products of lipoprotein lipase action. They have a triglyceride-depleted core and are enriched in cholesteryl esters. The main structural protein is apolipoprotein (apo)B48 in chylomicron remnants and apoB100 in very low-density lipoprotein remnants. A typical normal-sized low-density lipoprotein particle is shown for comparison. (B) Comparison of the cholesterol/apoB molar ratios in remnant-like particles isolated by immunoaffinity gel from the plasma of fasting subjects with Type III dyslipoproteinaemia, in which remnant particles accumulate, or borderline or moderately elevated triglyceride levels (data extracted from ref5). Only traces of remnant particles were detected in subjects with borderline elevated triglyceride levels. apo, apolipoprotein; CETP, cholesteryl ester transfer protein; HDL, high-density lipoprotein; HSPG, heparan sulphate proteoglycans; LDLr, low-density lipoprotein receptor; LRP1, low-density lipoprotein receptor-related protein 1; mol, molecules; RLP, remnant-like particle; RLP-C, remnant-like particle cholesterol; TG triglyceride; TRL, triglyceride-rich lipoproteins.CC BY-NC · PubMed Central
Figure 4 Overview of apolipoprotein B lipoprotein metabolism. During absorption of fat from the diet, chylomicrons are generated by the enterocytes in the small intestine, travel via lymphatics, and appear in the bloodstream. Lipidation of a primordial apolipoprotein (apo) B48-containing particle (apoB48, a truncated form of apoB100 made solely in the intestine) is mediated by microsomal triglyceride transfer protein using triglyceride synthesized from absorbed fatty acids. In a similar assembly process, a large triglyceride-rich, apoB100-containing very low-density lipoprotein (VLDL)1 is made in the liver using a variety of sources for triglyceride synthesis—de novo lipogenesis, fatty acids released from intracellular storage droplets, free fatty acids taken up from the circulation after their release from adipose tissue, and triglyceride fatty acids present in VLDL chylomicron remnants. Chylomicrons and VLDL1 (and to an extent VLDL2) compete for the same lipolytic mechanism. Lipoprotein lipase is anchored to the luminal surface of the capillary endothelium in skeletal muscle and adipose tissue by glycophosphatidylinositol-anchored high-density lipoprotein-binding protein-1. This enzyme hydrolyzes triglyceride in the core of the particle releasing fatty acids into the underlying tissue bed. Lipase maturation factor 1 is essential for the secretion of functional lipase from adipose tissue and muscle. ApoCII is an activator (essential cofactor) of lipoprotein lipase, whereas apoCIII is an inhibitor of the enzyme and of remnant particle uptake. The angiopoietin-like proteins 3, 4, and 8 (ANGPTL3, 4, 8) have a tissue-specific role in modifying (inhibiting) lipoprotein lipase action, whereas apoAV increases lipoprotein lipase-mediated lipolysis. Lipolysis of chylomicrons leads to the formation of remnant particles, which are cleared by the liver via the low-density lipoprotein receptors and, based on mouse studies, the low-density lipoprotein receptor-related protein 1. Likewise, VLDL1 is delipidated to VLDL2, remnants, and intermediate-density lipoproteins, which are either removed by liver receptors or converted to low-density lipoprotein as the final product. Smaller VLDL2 is also made by the liver and can be delipidated to intermediate-density lipoprotein and low-density lipoprotein (for more detail see refs43–45). It should be noted that lipolysis of both chylomicrons and VLDL in adipose tissue and skeletal muscle is neither equally divided nor randomly apportioned but is determined by insulin mediated regulation of lipoprotein lipase in each tissue, with insulin stimulating lipoprotein lipase in adipose tissue and inhibiting it in skeletal muscle. In addition, ANGPTL3 and ANGPTL8 inhibit lipoprotein lipase activity in skeletal muscle in the fed state and ANGPTL4 inhibits lipoprotein lipase activity in white adipose tissue during fasting.45 FFA, free fatty acids; GPIHBP1, glycophosphatidylinositol-anchored high-density lipoprotein-binding protein-1; IDL, intermediate-density lipoprotein; LDL, low-density lipoprotein; LDLr, low-density lipoprotein receptor; LMF1, lipase maturation factor 1; LRP1, low-density lipoprotein receptor-related protein 1; MTP, microsomal triglyceride transfer protein; VLDL, very low-density lipoprotein.
Figure 4 Overview of apolipoprotein B lipoprotein metabolism. During absorption of fat from the diet, chylomicrons are generated by the enterocytes in the small intestine, travel via lymphatics, and appear in the bloodstream. Lipidation of a primordial apolipoprotein (apo) B48-containing particle (apoB48, a truncated form of apoB100 made solely in the intestine) is mediated by microsomal triglyceride transfer protein using triglyceride synthesized from absorbed fatty acids. In a similar assembly process, a large triglyceride-rich, apoB100-containing very low-density lipoprotein (VLDL)1 is made in the liver using a variety of sources for triglyceride synthesis—de novo lipogenesis, fatty acids released from intracellular storage droplets, free fatty acids taken up from the circulation after their release from adipose tissue, and triglyceride fatty acids present in VLDL chylomicron remnants. Chylomicrons and VLDL1 (and to an extent VLDL2) compete for the same lipolytic mechanism. Lipoprotein lipase is anchored to the luminal surface of the capillary endothelium in skeletal muscle and adipose tissue by glycophosphatidylinositol-anchored high-density lipoprotein-binding protein-1. This enzyme hydrolyzes triglyceride in the core of the particle releasing fatty acids into the underlying tissue bed. Lipase maturation factor 1 is essential for the secretion of functional lipase from adipose tissue and muscle. ApoCII is an activator (essential cofactor) of lipoprotein lipase, whereas apoCIII is an inhibitor of the enzyme and of remnant particle uptake. The angiopoietin-like proteins 3, 4, and 8 (ANGPTL3, 4, 8) have a tissue-specific role in modifying (inhibiting) lipoprotein lipase action, whereas apoAV increases lipoprotein lipase-mediated lipolysis. Lipolysis of chylomicrons leads to the formation of remnant particles, which are cleared by the liver via the low-density lipoprotein receptors and, based on mouse studies, the low-density lipoprotein receptor-related protein 1. Likewise, VLDL1 is delipidated to VLDL2, remnants, and intermediate-density lipoproteins, which are either removed by liver receptors or converted to low-density lipoprotein as the final product. Smaller VLDL2 is also made by the liver and can be delipidated to intermediate-density lipoprotein and low-density lipoprotein (for more detail see refs43–45). It should be noted that lipolysis of both chylomicrons and VLDL in adipose tissue and skeletal muscle is neither equally divided nor randomly apportioned but is determined by insulin mediated regulation of lipoprotein lipase in each tissue, with insulin stimulating lipoprotein lipase in adipose tissue and inhibiting it in skeletal muscle. In addition, ANGPTL3 and ANGPTL8 inhibit lipoprotein lipase activity in skeletal muscle in the fed state and ANGPTL4 inhibits lipoprotein lipase activity in white adipose tissue during fasting.45 FFA, free fatty acids; GPIHBP1, glycophosphatidylinositol-anchored high-density lipoprotein-binding protein-1; IDL, intermediate-density lipoprotein; LDL, low-density lipoprotein; LDLr, low-density lipoprotein receptor; LMF1, lipase maturation factor 1; LRP1, low-density lipoprotein receptor-related protein 1; MTP, microsomal triglyceride transfer protein; VLDL, very low-density lipoprotein.CC BY-NC · PubMed Central
Figure 5 Metabolism of remnant lipoproteins. Remnants are a population of particles in the circulation that have been partially lipolysed by lipoprotein lipase. Efficient lipolysis (broad green arrow) leads to rapid conversion to low-density lipoprotein, with little remnant formation. Causes of remnant accumulation are overproduction of triglyceride-rich lipoproteins or compromised (but not completely absent) lipase action (red arrows). ‘Transient’ remnants in the very low-density lipoprotein/intermediate-density lipoprotein range are converted to low-density lipoprotein; chylomicron remnants are not converted to low-density lipoproteins (see Graphical Abstract and Figure 4). Inefficient lipolysis increases the residence time of remnants and they undergo remodelling, acquiring cholesterol (specifically cholesteryl ester by transfer mediated by cholesteryl ester transfer protein), and apolipoprotein (apo) E. This remodelling can lead to a particle that is no longer susceptible to lipolysis—an ‘end-product’ remnant—with a prolonged residence time in the circulation.44 CETP, cholesteryl ester transfer protein; IDL, intermediate-density lipoprotein; LDL, low-density lipoprotein; LpL, lipoprotein lipase; VLDL, very low-density lipoprotein.
Figure 5 Metabolism of remnant lipoproteins. Remnants are a population of particles in the circulation that have been partially lipolysed by lipoprotein lipase. Efficient lipolysis (broad green arrow) leads to rapid conversion to low-density lipoprotein, with little remnant formation. Causes of remnant accumulation are overproduction of triglyceride-rich lipoproteins or compromised (but not completely absent) lipase action (red arrows). ‘Transient’ remnants in the very low-density lipoprotein/intermediate-density lipoprotein range are converted to low-density lipoprotein; chylomicron remnants are not converted to low-density lipoproteins (see Graphical Abstract and Figure 4). Inefficient lipolysis increases the residence time of remnants and they undergo remodelling, acquiring cholesterol (specifically cholesteryl ester by transfer mediated by cholesteryl ester transfer protein), and apolipoprotein (apo) E. This remodelling can lead to a particle that is no longer susceptible to lipolysis—an ‘end-product’ remnant—with a prolonged residence time in the circulation.44 CETP, cholesteryl ester transfer protein; IDL, intermediate-density lipoprotein; LDL, low-density lipoprotein; LpL, lipoprotein lipase; VLDL, very low-density lipoprotein.CC BY-NC · PubMed Central
Figure 6 Causes of hypertriglyceridaemia in the population. This schematic representation illustrates the distribution of plasma triglyceride levels in a population (adapted from a survey of >100 000 individuals in the Copenhagen General Population Study).17 The distribution is segmented by colours according to the triglyceride cut-points in Box 1, i.e. optimal triglyceride <1.2 mmol/L (green), borderline elevated, 1.2–1.7 mmol/L (yellow), moderately elevated, 1.7–5.7 mmol/L (pink), and severe or extreme hypertriglyceridaemia, >5.7 mmol/L (brown). (Note plasma samples in this survey were non-fasting whereas cut-points in Box 1 are for fasting values). Increased production of very low-density lipoprotein in the liver is the primary abnormality leading to higher levels of triglyceride-rich lipoproteins and remnants in individuals with borderline/moderately increased plasma triglyceride, whereas decreased lipolysis is the predominant feature at higher triglyceride concentrations, with accumulation of both very low-density lipoprotein and chylomicrons. Individuals with the most severe forms of hypertriglyceridaemia, particularly those with monogenic causes, may have normal production rates and extremely low levels of lipolysis. TG, triglyceride; VLDL, very low-density lipoprotein.
Figure 6 Causes of hypertriglyceridaemia in the population. This schematic representation illustrates the distribution of plasma triglyceride levels in a population (adapted from a survey of >100 000 individuals in the Copenhagen General Population Study).17 The distribution is segmented by colours according to the triglyceride cut-points in Box 1, i.e. optimal triglyceride <1.2 mmol/L (green), borderline elevated, 1.2–1.7 mmol/L (yellow), moderately elevated, 1.7–5.7 mmol/L (pink), and severe or extreme hypertriglyceridaemia, >5.7 mmol/L (brown). (Note plasma samples in this survey were non-fasting whereas cut-points in Box 1 are for fasting values). Increased production of very low-density lipoprotein in the liver is the primary abnormality leading to higher levels of triglyceride-rich lipoproteins and remnants in individuals with borderline/moderately increased plasma triglyceride, whereas decreased lipolysis is the predominant feature at higher triglyceride concentrations, with accumulation of both very low-density lipoprotein and chylomicrons. Individuals with the most severe forms of hypertriglyceridaemia, particularly those with monogenic causes, may have normal production rates and extremely low levels of lipolysis. TG, triglyceride; VLDL, very low-density lipoprotein.CC BY-NC · PubMed Central
Figure 7 Role of triglyceride-rich lipoproteins and remnants in atherogenesis. Because of their size (<70 nm), chylomicron remnants, very low-density lipoprotein remnants, and intermediate-density lipoprotein can enter the artery wall by transcytosis across the endothelial layer. With elevated plasma levels, rates of influx exceed egress resulting in accumulation of particles in the subendothelial space. These lipoprotein particles can adhere to extracellular matrix (proteoglycans), an interaction enhanced by the presence of apolipoprotein (apo) CIII and apoE on the particle surface. In situ degradation of these particles releases bioactive lipids, which cause endothelial dysfunction and inflammation. Monocyte-macrophages are recruited from the circulation to clear the deposited lipoproteins, and uptake of cholesterol-enriched lipoproteins leads to foam cell formation and the appearance of early lesions (A). With repeated cycles of lipoprotein ingress and macrophage migration, a fatty streak is generated (B). Further cellular changes include migration of medial smooth muscle cells into the lesion area. Eventually an unstable complex plaque forms, which upon surface erosion or mechanical rupture may lead to thrombus formation, and potentially lumen occlusion with an ensuing clinical event. CE, cholesteryl ester; IDL, intermediate-density lipoprotein; VLDL, very low-density lipoprotein.
Figure 7 Role of triglyceride-rich lipoproteins and remnants in atherogenesis. Because of their size (<70 nm), chylomicron remnants, very low-density lipoprotein remnants, and intermediate-density lipoprotein can enter the artery wall by transcytosis across the endothelial layer. With elevated plasma levels, rates of influx exceed egress resulting in accumulation of particles in the subendothelial space. These lipoprotein particles can adhere to extracellular matrix (proteoglycans), an interaction enhanced by the presence of apolipoprotein (apo) CIII and apoE on the particle surface. In situ degradation of these particles releases bioactive lipids, which cause endothelial dysfunction and inflammation. Monocyte-macrophages are recruited from the circulation to clear the deposited lipoproteins, and uptake of cholesterol-enriched lipoproteins leads to foam cell formation and the appearance of early lesions (A). With repeated cycles of lipoprotein ingress and macrophage migration, a fatty streak is generated (B). Further cellular changes include migration of medial smooth muscle cells into the lesion area. Eventually an unstable complex plaque forms, which upon surface erosion or mechanical rupture may lead to thrombus formation, and potentially lumen occlusion with an ensuing clinical event. CE, cholesteryl ester; IDL, intermediate-density lipoprotein; VLDL, very low-density lipoprotein.CC BY-NC · PubMed Central

Verification

Claims the paper makes

33 Valid · 11 Not valid · 56 Not checked · 51 Own results and interpretations

66 more claims · 15 with their cited sources checked

Create a free account to see all 151 claims and to verify the 133 references still open.

See all claims — free account
  • It may state two separate claims as one. 70
  • Probably not a substantial claim. 16

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 212 references

Cited by

See all 1,000

Metadata

Authors
Ginsberg, H. N., Packard, C. J., Chapman, M. J., Borén, J., Aguilar-Salinas, C. A., Averna, M., Ference, B. A., Gaudet, D., Hegele, R. A., Kersten, S., Lewis, G. F., Lichtenstein, A. H., Moulin, P., Nordestgaard, B. G., Remaley, A. T., Staels, B., Stroes, E. S. G., Taskinen, M.-R., Tokgözoğlu, L. S., Tybjaerg-Hansen, A., Stock, J. K., & Catapano, A. L.
Affiliations
  • Columbia University (US)
  • University of Glasgow (GB)
  • Inserm (FR)
  • Sahlgrenska University Hospital (SE)
  • Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (MX)
  • University of Palermo (IT)
  • University of Cambridge (GB)
  • Université de Montréal (CA)
  • Western University (CA)
  • Wageningen University & Research (NL)
  • University of Toronto (CA)
  • Tufts University (US)
  • University of Copenhagen (DK)
  • National Institutes of Health (US)
  • Amsterdam UMC Location University of Amsterdam (NL)
  • University of Helsinki (FI)
  • Hacettepe University (TR)
  • Department of Clinical Biochemistry, Blegdamsvej 9, Rigshospitalet , Copenhagen 2100, Denmark
  • European Atherosclerosis Society (SE)
  • University of Milan (IT)
Corresponding author
Ginsberg, Henry N
Venue
European Heart Journal
Published
2021-09-02
Volume
42
Issue
47
Pages
4791-4806
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W3197326839
Cited by
979
References
212
Citations by year
2026: 253 · 2025: 237 · 2024: 206 · 2023: 164 · 2022: 108 · 2021: 10
FWCI
81.79
Type
journal article
Language
en
Open access
Locations
  • European Heart Journal (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by-nc)
  • Socio-Environmental Systems Modeling (submittedVersion, cc-by-nc)
  • HAL (submittedVersion, cc-by-nc)
  • Työväentutkimus Vuosikirja (submittedVersion)
  • Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
  • LillOA (Université de Lille (University Of Lille)) (submittedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion, cc-by-nc)
Funders
The European Atherosclerosis Society Consensus Panel
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
triglyceride-rich lipoproteins, remnant lipoproteins, atherosclerotic cardiovascular disease, hypertriglyceridemia, residual cardiovascular risk, lipolysis, atherogenicity, LDL-C lowering therapy, therapeutic target, myocardial infarction, ischemic stroke, aortic stenosis
MeSH terms
Cardiovascular Diseases, Brain Ischemia, Humans, Lipoproteins, Triglycerides, Stroke, Atherosclerosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society. https://app.cochat.ai/papers/10.1093/eurheartj/ehab551
The paper
Ginsberg, H. N., Packard, C. J., Chapman, M. J., Borén, J., Aguilar-Salinas, C. A., Averna, M., Ference, B. A., Gaudet, D., Hegele, R. A., Kersten, S., Lewis, G. F., Lichtenstein, A. H., Moulin, P., Nordestgaard, B. G., Remaley, A. T., Staels, B., Stroes, E. S. G., Taskinen, M.-R., Tokgözoğlu, L. S., . . . Catapano, A. L. (2021). Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society. European Heart Journal. https://doi.org/10.1093/eurheartj/ehab551

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.